The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective
Authors:
- Anton PottegårdAPAnton Pottegård
- Bine Kjøller BjerregaardBBBine Kjøller Bjerregaard
- Dorte GlintborgDGDorte Glintborg
- Jesper HallasJHJesper Hallas
- Søren Ilsøe MorenoSMSøren Ilsøe Moreno
- 21 March 2012
- journal article
- pharmacoepidemiology and-prescription
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 68 (10) , 1443-1450
Abstract
Purpose The purpose of the study was to characterize the utilization of medication against attention deficit hyperactivity disorder (ADHD) in Denmark between 1995 and 2011 from a national perspective, by using population-based prescription data. Methods National data on drug use in Denmark between 1 January 1995 and 30 September 2011 were extracted from the Registry of Medicinal Product Statistics (RMPS). Drug utilization was characterized using descriptive statistics. Results A total of 1,085,090 prescriptions issued to 54,020 persons were identified. The incidence rate was stable in the last 3 years of the study period, and a slightly decreasing incidence rate and a stabilizing prevalence were observed towards the end of this period. The therapeutic intensity was 6.7 defined daily dose/person/day, with large regional differences that ranged from 64 to 145 % of the national average. Methylphenidate accounted for 92.6 % of DDDs used. The general practitioner (GP) rarely initiated treatment, although treatment initiation based on the GP’s advice increased with older age of the patient. Maintenance treatment was found to be distributed roughly equally between prescriber types. For methylphenidate, 1 % of users accounted for 6.1 % of the drug volume and 50 % of users accounted for 84.4 %. The data therefore do not suggest a high proportion of heavy users. Conclusion The findings of this analysis are mostly reassuring, with the data indicating a seemingly stagnant incidence and prevalence rate and lacking evidence of heavy users. However, the prescriber profile for incident users and the large regional variances raise concerns. It is therefore vital that the use of ADHD drugs is closely monitored.Keywords
This publication has 18 references indexed in Scilit:
- ADHD Drugs and Serious Cardiovascular Events in Children and Young AdultsNew England Journal of Medicine, 2011
- The Danish National Prescription RegistryScandinavian Journal of Public Health, 2011
- Use of ADHD drugs in the Nordic countries: a population-based comparison studyActa Psychiatrica Scandinavica, 2010
- Attention deficit hyperactivity disorder in adultsThe World Journal of Biological Psychiatry, 2010
- Large increase of the use of psycho‐stimulants among youth in the Netherlands between 1996 and 2006British Journal of Clinical Pharmacology, 2009
- Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the LiteratureJournal of the American Academy of Child & Adolescent Psychiatry, 2008
- Epidemiology of attention-deficit/hyperactivity disorder across the lifespanCurrent Opinion in Psychiatry, 2007
- Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorderThe British Journal of Psychiatry, 2007
- Templates for Analysis of Individual‐Level Prescription DataBasic & Clinical Pharmacology & Toxicology, 2006
- National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: 24-Month Outcomes of Treatment Strategies for Attention-Deficit/Hyperactivity DisorderPediatrics, 2004